Cross-linked magnetic dextran nanoparticles (nanomag®-CLD)

  • are prepared via the core-shell method with a core of magnetite and a dextran shell,
  • are available with particle diameters of 300 nm and 500 nm for separation with a permanent magnet,
  • consist of 80-90% (w/w) magnetite in a matrix of crosslinked dextran,
  • are designed with NH2, COOH and PEG-COOH for the covalent binding of proteins, antibodies or other molecules,
  • are available with covalently bound streptavidin,
  • other protein surfaces are available on request.

Showing all 8 results

  • Krukemeyer, M.G., Krenn, V., Jakobs, M., and Wagner, W., Mitoxantrone-iron oxide biodistribution in blood, tumor, spleen, and liver-magnetic nanoparticles in cancer treatment, J Surg Res, 2011, 175, 35-43;
  • Krukemeyer, M.G., Krenn, V., Jakobs, M., and Wagner, W., Magnetic drug targeting in a rhabdomyosarcoma rat model using magnetite-dextran composite nanoparticle-bound mitoxantrone and 0.6 tesla extracorporeal magnets - sarcoma treatment in progress, Journal of drug Targeting, 2012, 185-93;
  • Kanazaki, K., Honma, T., Yamauchi, F., Ogawa, S., and Inoue, S., Composite particle, contrast agent for photoacoustic imaging and method for producting the composite particle, US 0294987, 2011;
Sub categories: